MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. NHC
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

National HealthCare (NHC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

National HealthCare
NYSE American•Healthcare•Medical Care Facilities
$224.84-0.52(<0.01%)Pre-market
Market Cap
$3.51B
P/E
25.0x
P/S
2.3x
P/B
3.1x

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. It operates through two segments: Inpatient and Homecare and Hospice Services. The company's skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. It provides medical specialty units comprise memory care units and sub-acute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, the company offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

B

How this company scores

GoodMetricSide Score: 77/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability19/25
Growth20/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality23/25
Strengths
Rising free cash flowRising earningsInterest easily coveredConsistent free cash flow

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 25.0x5y range 7.3x – 46.7x
P/E 25.0x · above its 20-quarter median

Currently above its 20-quarter median.

P/S · 2.3x5y range 0.8x – 2.3x
P/S 2.3x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 3.1x5y range 1.0x – 3.1x
Price & Volume
Market Cap $3.51B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.56B
7Q
Q. Revenue
$408.02M
9%
TTM EBITDA
$190.40M
7Q
TTM Op. Income
$144.68M
7Q
Q. Op. Income
$48.94M
44%
TTM Net Income
$140.26M
3Q
Q. Net Income
$40.32M
2Q
EPS
$2.58
2Q
Shares Out.
$15.62M
7Q
$1.56B in TTM revenue grew 6.9% YoY, reaching $408.02M last quarter. TTM EBITDA of $190.40M and TTM operating income of $144.68M show growth is flowing through to the bottom line. TTM net income of $140.26M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
14.7%
22%
Op. Margin
12.0%
32%
Net Margin
9.9%
2Q
Op. margin of 12.0% is up 2.9% YoY — cost efficiency is improving. Net margin at 9.9% Over the past year, operating margin is up 32% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
25.0x
2Q
P/S Ratio
2.3x
5Q
P/B Ratio
3.1x
5Q
At 25.0x P/E, the stock trades within typical market levels. P/S of 2.3x and P/B of 3.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$1.54B
2%
Cash
$39.21M
3Q
Long-Term Debt
N/A
5Q
Book Value
$1.12B
6Q
D/E Ratio
N/A
5Q
Debt/EBITDA
0.0
100%

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$43.27M
31%
TTM Free Cash Flow
$146.53M
23%
FCF Margin
9.4%
15%
FCF / Net Income
1.0
8%
TTM FCF of $146.53M on $43.27M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 23% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 3.1x
· above its 20-quarter median

Currently above its 20-quarter median.